Quintiles opens new central lab in Japan
Wholly owned facility in Tokyo adds to Asian lab network
Quintiles has relocated its Global Central Laboratory in Japan from Saitama to Tokyo to allow for expansion as the US biopharmaceutical services firm continues to grow its business in Japan and Asia-Pacific.
The lab will initially focus on safety testing as it extends it capabilities. It has started receiving and testing clinical trial samples and has been certified to National Glycohaemoglobin Standardisation Programme Level 1 for diabetes testing.
‘The growth of clinical research in Asia-Pacific is driving this move as we continue to reduce complexity and help our customers get new medicines to patients faster,’ said Alan Ong, vice president and general manager of Quintiles Global Central Laboratories Asia.
Quintiles Global Central Laboratories develops biomarker assays to support clinical development of targeted therapies and other personalised medicine advances.
The lab in Japan is taking steps toward certification by the College of American Pathologists (CAP).
